Amount Of HER-2 Gene Amplification As Assessed By FISH Is Linked To Magnitude Of Survival Benefit In Patients With Locally Advanced Breast Cancer

Patients with locally advanced breast cancers whose tumours contain high numbers of copies of the gene for the human epidermal growth factor receptor 2 (HER-2), as assessed by fluorescence in situ hybridization (FISH), are more likely to have a complete response to treatment with an antibody to the receptor than patients with fewer copies of the gene in their tumours. [click link for full article]

More: continued here

Filed under: Breast Cancer on December 20th, 2007